Cargando…
mTOR Signaling and Potential Therapeutic Targeting in Meningioma
Meningiomas are the most frequent primary tumors arising in the central nervous system. They typically follow a benign course, with an excellent prognosis for grade I lesions through surgical intervention. Although radiotherapy is a good option for recurrent, progressive, or inoperable tumors, alter...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876623/ https://www.ncbi.nlm.nih.gov/pubmed/35216092 http://dx.doi.org/10.3390/ijms23041978 |
_version_ | 1784658217463185408 |
---|---|
author | Pinker, Benjamin Barciszewska, Anna-Maria |
author_facet | Pinker, Benjamin Barciszewska, Anna-Maria |
author_sort | Pinker, Benjamin |
collection | PubMed |
description | Meningiomas are the most frequent primary tumors arising in the central nervous system. They typically follow a benign course, with an excellent prognosis for grade I lesions through surgical intervention. Although radiotherapy is a good option for recurrent, progressive, or inoperable tumors, alternative treatments are very limited. mTOR is a protein complex with increasing therapeutical potential as a target in cancer. The current understanding of the mTOR pathway heavily involves it in the development of meningioma. Its activation is strongly dependent on PI3K/Akt signaling and the merlin protein. Both factors are commonly defective in meningioma cells, which indicates their likely function in tumor growth. Furthermore, regarding molecular tumorigenesis, the kinase activity of the mTORC1 complex inhibits many components of the autophagosome, such as the ULK1 or Beclin complexes. mTOR contributes to redox homeostasis, a vital component of neoplasia. Recent clinical trials have investigated novel chemotherapeutic agents for mTOR inhibition, showing promising results in resistant or recurrent meningiomas. |
format | Online Article Text |
id | pubmed-8876623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88766232022-02-26 mTOR Signaling and Potential Therapeutic Targeting in Meningioma Pinker, Benjamin Barciszewska, Anna-Maria Int J Mol Sci Review Meningiomas are the most frequent primary tumors arising in the central nervous system. They typically follow a benign course, with an excellent prognosis for grade I lesions through surgical intervention. Although radiotherapy is a good option for recurrent, progressive, or inoperable tumors, alternative treatments are very limited. mTOR is a protein complex with increasing therapeutical potential as a target in cancer. The current understanding of the mTOR pathway heavily involves it in the development of meningioma. Its activation is strongly dependent on PI3K/Akt signaling and the merlin protein. Both factors are commonly defective in meningioma cells, which indicates their likely function in tumor growth. Furthermore, regarding molecular tumorigenesis, the kinase activity of the mTORC1 complex inhibits many components of the autophagosome, such as the ULK1 or Beclin complexes. mTOR contributes to redox homeostasis, a vital component of neoplasia. Recent clinical trials have investigated novel chemotherapeutic agents for mTOR inhibition, showing promising results in resistant or recurrent meningiomas. MDPI 2022-02-10 /pmc/articles/PMC8876623/ /pubmed/35216092 http://dx.doi.org/10.3390/ijms23041978 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pinker, Benjamin Barciszewska, Anna-Maria mTOR Signaling and Potential Therapeutic Targeting in Meningioma |
title | mTOR Signaling and Potential Therapeutic Targeting in Meningioma |
title_full | mTOR Signaling and Potential Therapeutic Targeting in Meningioma |
title_fullStr | mTOR Signaling and Potential Therapeutic Targeting in Meningioma |
title_full_unstemmed | mTOR Signaling and Potential Therapeutic Targeting in Meningioma |
title_short | mTOR Signaling and Potential Therapeutic Targeting in Meningioma |
title_sort | mtor signaling and potential therapeutic targeting in meningioma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876623/ https://www.ncbi.nlm.nih.gov/pubmed/35216092 http://dx.doi.org/10.3390/ijms23041978 |
work_keys_str_mv | AT pinkerbenjamin mtorsignalingandpotentialtherapeutictargetinginmeningioma AT barciszewskaannamaria mtorsignalingandpotentialtherapeutictargetinginmeningioma |